Day Zero Diagnostics raises $8.2M from CARB-X

Day Zero Diagnostics announced that it received an $8.2 million award in optional stage funding from CARB-X.

The infectious disease diagnostic developer received an initial $6.2 million CARB-X award in May 2020. CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, aims to accelerate early antibacterial R&D. This would address the rising global threat of drug-resistant bacteria.

Day Zero’s total award funding now sits at more than $16 million. The company also completed a venture equity financing worth $21 million in February.

Anti-biotic-resistant infections remain on the rise. Worries persist that superbugs could eventually evolve to the point that antibiotics no longer work effectively. In 2020, more than 20 biopharmaceutical companies around the world pledged more than $1 billion toward the Antimicrobial Resistance (AMR) Action Fund.

Day Zero develops whole genome sequencing-based diagnostic technologies.…

Read more
  • 0

Day Zero Diagnostics raises $21M

Infectious disease diagnostic company Day Zero Diagnostics announced today that it completed a venture equity financing worth $21 million.

Sands Capital led the financing round, while significant participation came from new investors including BD, Panacea Venture and Hongkou Capital, along with existing investors including Triventures and Golden Seeds.

To date, Zero Day Diagnostics has raised more than $33 million in venture capital financing and more than $10 million in non-dilutive funding, according to a news release. In May 2020, the company received $6.2 million of that non-dilutive funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

Boston-based Day Zero Diagnostics’ develops sequencing-based diagnostic technologies for identifying the species and antibiotic resistance profile of a bacterial pathogen within hours. The company’s approach aims to save lives while reducing the economic burden of…

Read more
  • 0